|本期目录/Table of Contents|

[1]杨英亮,郝玲.替罗非班在尿激酶静脉溶栓后进展性脑梗死治疗中的应用效果[J].慢性病学杂志,2020,21(10):1492-1494.
　YANGYing-liang,HAOLing.Application value of tirofiban in the treatment of progressive cerebral infarction after intravenous thrombolysis with urokinase[J].,2020,21(10):1492-1494.
点击复制

替罗非班在尿激酶静脉溶栓后进展性脑梗死治疗中的应用效果

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
21
期数:
2020年10期
页码:
1492-1494
栏目:
论　著
出版日期:
2020-09-28

文章信息/Info

Title:
Application value of tirofiban in the treatment of progressive cerebral infarction after intravenous thrombolysis with urokinase
作者:
杨英亮; 郝玲
寿光市人民医院神经内一科，山东 寿光 262700
Author(s):
YANGYing-liang; HAOLing
First Departmentof Neurology, Shouguang People’sHospital,Shouguang, Shandong262700,China Correspondingauthor:HAOLing,E-mail:276132728@qq.com
关键词:
进展性脑梗死; 替罗非班; 尿激酶
Keywords:
Progressive cerebral infarction;  Tirofiban;  Urokinase
分类号:
R743.3
DOI:
-
摘要:
目的 探讨替罗非班在尿激酶静脉溶栓后进展性脑梗死治疗中的安全性和有效性。方法 选取2016年 10月—2019年10月寿光市人民医院神经内一科收治的40例经尿激酶静脉溶栓后出现进展性脑梗死患者，随机分 为替罗非班组和对照组，每组20例。替罗非班组在患者出现进展时立即予以替罗非班静脉泵入[持续0.1 μg/（kg·min）静脉泵入24 h]治疗，替罗非班泵完结束前4 h给予阿司匹林。对照组不予替罗非班，静脉溶 栓后常规24 h后予以阿司匹林。观察两组间14d内颅内外出血事件、14 d内病死率、治疗7 d及14 d时美国国 立卫生院卒中量表（NIHSS）评分、3个月时改良Rankin量表评分（mRS）等指标。结果 治疗7 d及14 d， 观察组NIHSS评分低于对照组，差异均有统计学意义（P<0.05）。两组14d病死率均为0，颅内外出血事件发生 率（5.00% vs.5.00%）比较，差异均无统计学意义（P>0.05）；观察组3个月时预后良好（mRS评分：0~2分） 率为60.00%，高于对照组的25.00%，差异有统计学意义（χ 2＝5.01，P<0.05）。结论 对尿激酶静脉溶栓后进 展性脑梗死患者，立即予以替罗非班静脉泵入并不增加出血事件及病死率的发生，且能明显改善患者预后。
Abstract:
Objective To investigate the safety and efficacy of tirofiban in the treatment of progressive cerebral infarction after intravenous thrombolysis with urokinase. Methods Forty patients with progres-sive cerebral infarction after intravenous thrombolysis with urokinase were randomly divided into two groups: tirofiban group（n=20）and control group（n=20）. Patients in the tirofiban group were intrave-nously pumped into tirofiban [0.1 μg/（kg· min）for 24 h] immediately when the patients made prog-ress, and aspirin was given 4 h before the end of the pump. The control group only received aspirin treatment 24 h after intravenous thrombolysis. The incidences of intracranial hemorrhage, systematic bleed-ings and death during the first 14 d were recorded. The National Institutes of Health Stroke score（NI-HSS）after 7 days and 14 d of treatment, and modified Rankin scale（mRS）after 3 months were as-sessed. Results After7 d and 14 d of treatment, the average NIHSS scores in tirofiban group were significantly lower than those in control group（P<0.05）. There was no dead patient in both groups. There was no significant difference in the incidence of intracranial hemorrhage during the first14 d be-tween the two groups（5.00% vs.5.00%,P>0.05）. In the 3 months after treatment, there was signifi-cant difference in the rate of good prognosis（mRs:0-2）between the tirofiban group and the control group（60.00% vs.25.00%,χ 2＝5.01, P<0.05）. Conclusion Intravenous tirofiban does not increasethe bleeding events or mortality for patients with progressive cerebral infarction after intravenous thrombol-ysis with urokinase, and it can significantly improve the prognosis of patients.

参考文献/References:

[1] 陈胜云,王丹丹,杨中华,等.静脉应用阿替普酶在急性缺血性卒 中治疗中的应用[J].中国卒中杂志,2016,11(10):821-823. [2] 陈晓能,孔令恩,蔡春生.完善绿色通道及溶栓流程对提高急性缺 血性脑卒中静脉溶栓率的应用评价[J].中国实用医药,2017,12 (1):182-184. [3] 鲁明.缺血性卒中急性期静脉溶栓后抗血小板聚集药物使用的研 究进展[J].中国脑血管病杂志,2016,13(7):381-383. [4] 徐荣薇.进展性缺血性脑卒中的相关因素分析[J].中国实用神经 疾病杂志,2018,21(11):1263-1266. [5] 中华神经科学会.各类脑血管疾病诊断要点(1995)[J].临床和实验 医学杂志,2013,12(7):559. [6] von Kummer R, Broderick JP, Campbell BC, et al. The heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy [J]. Stroke,2015,46:2981-2986. [7] 丁琪，陈旭.静脉溶栓对中老年急性脑梗死合并脑微出血的影响 [J].中国老年学杂志,2018,38(21):5147-5149. [8] 李坷,张继中,张钦昌.国产替罗非班在急性进展性脑梗死治疗中 的应用[J].中国实用神经疾病杂,2017,20(1):117-118. [9] 刘小洲.替罗非班治疗进展性脑梗死的疗效及安全性评估[J].中 国医院药学杂志,2014,(18):1600-1603. [10] D Stegner, C Deppermann, P Kraft,et al. Munc13-4-mediated secretion is essential for infarct progression but not intracranial hemostasis in acute stroke [J]. Thromb Haemost,2013,11(7):1430-1433. [11] 杨玉峰,张殿印,侯玉芹.尿激酶静脉溶栓后早期血管再闭塞的原 因分析[J].中国实用神经疾病杂志,2009,12(4):10-12. [12] 杨金波,马晓丹,马晓辉,等.尿激酶联合替罗非班治疗基底动脉 闭塞再通二例[J].脑与神经疾病杂志,2017,25(12):776-780. [13] 冯雷,潘力,冯光,等.替罗非班联合尿激酶超选择动脉溶栓治疗 急性大脑中动脉栓塞的实验研究[J].天津医药,2011,39(12): 1150-1152. [14] Kang DH, Kim YW, Hwang YH,et al. Instant reocclu-sion following mechanical thrombectomy of in situ throm-boocclusion and the role of low-dose intra-arterial tirofiban [J]. Cerebrobasc Dis, 2014,37(5):350-355. [15] Seo JH, Jeonq HW, Kim ST, et al. Adjuvant tirofiban injection through deployed solitaire stent as a rescue tech-nique after failed mechanical thrombectomy in acute stroke [J]. Neurointervention, 2015,10(1):22-27. [16] 景宏菲,王艳芳,等.联合运用尿激酶和替罗非班治疗急性脑梗死 的安全性和有效性[J].临床荟萃,2018,33(5):409-412. [17] 张芬.替罗非班在急性脑卒中溶栓后再闭塞患者治疗中的价值与 安全性分析[J].蛇志,2019,31(1):39-41.

备注/Memo

备注/Memo:
作者简介：杨英亮，大学本科，中级，研究方向：神经内科学 通信作者：郝玲，E-mail:276132728@qq.com
更新日期/Last Update: 2020-09-28